WOCKHARDT LTD. - Updates

Download	< Back
21 Mar 2017
This is to inform the Exchanges that abbreviated new drug application (ANDA') of Piperacillin and Tazobactam for Injection USP, 40.5 g/vial, pharmacy bulk package submitted by Wockhardt Bio AG (Wockhardt), Subsidiary of the Company has been approved by U.S. Food and Drug Administration ('USFDA'). Wockhardt's ANDA was determined to be therapeutically equivalent to the reference listed drug (RLD) Zosyn for Injection 40.5g/vial, pharmacy bulk package of Wyeth Pharmaceuticals Inc. Wockhardt Bio AG had filed this ANDA in collaboration with Fresinius Kabi, Italy (FKAI'), where the product development was completed. The ANDA will be manufactured commercially at FKAI, Mitim, Italy.
View all announcements for WOCKHARDT LTD.	Source: BSE India

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2024	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us